Amneal launches Clolar generic
Amneal’s biosciences arm recently introduced its generic of Clolar (clofarabine, 1mg/ml). The Bridgewater, N.J.-based company will be shipping the product in a single-dose vial containing 20 mg of the active ingredient in 20 ml of clear sterile solution.
“We are pleased to expand our product portfolio with clofarabine,” Amneal Biosciences president Charles Lucarelli said. “It’s an important addition to our growing oncology line.”
The product had $53 million in sales for the 12 months ended September 2017, according to data from IQVIA.
FDA approves Breckenridge’s Megace ES generic
The Food and Drug Administration has approved Breckenridge Pharmaceuticals’ generic of Megace ES (megestrol acetate oral suspension).
The drug is a concentrated suspension that is indicated to treat loss of appetite, severe malnutrition or unexplained significant weight loss in patients with AIDS. The drug had generic and brand sales of $17.6 million for the 12 months ended October 2017, according to IQVIA data.
The Boca Raton, Fla.-based company said the product was launching immediately, having resolved litigation between it, Par Pharmaceuticals and Alkermes Pharma Ireland.
Mylan, Aspen launch generic Myleran
Mylan is launching its latest generic with its partner, South Africa-based Aspen. The companies are introducing their generic of Otsuka’s Myleran (busulfan, 6 mg/ml) injection.
The product is indicated in combination with cyclophosphamide as a conditioning regimen ahead of allogeneic hematopoietic progenitor cell transplantation in patients with chronic myelogenous leukemia. Mylan said that it has one of the largest injectables portfolios in the industry, and is among the leading cancer medicines suppliers by volume in the United States.
Mylan will commercialize the single-dose vial product in the United States. The drug had U.S. market size of roughly $97 million for the 12 months ended Sept. 30, according to IQVIA data.